Fishman Retires from Novartis; New Research Head Appointed
This article was originally published in Scrip
Executive Summary
Novartis AG has named Dr. James E. Bradner president of the Novartis Institutes for BioMedical Research (NIBR) and a member of the company's executive committee – effective March 1, 2016. Bradner will replace Dr. Mark C. Fishman, who is retiring after 13-years leading Novartis's discovery and early clinical development efforts.